This review outlines the pathogenesis, diagnosis, and management of non-alcoholic fatty liver disease, highlighting its growing health burden.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to NAFLD's rising burden; extends evidence synthesis but leaves optimal strategies open for prospective trials.
Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder in western countries, and its incidence is increasing. This review outlines the significant health burden posed by NAFLD and discusses what is presently known about its pathogenesis, including the roles of the metabolic syndrome, obesity, insulin resistance, hepatic steatosis, reactive oxygen species, inflammatory cytokines and adipocytokines. The way in which NAFLD is clinically diagnosed is described, and areas of uncertainty surrounding its investigation are identified, before discussing the relative merits of the limited treatment options available and looking ahead to potential therapeutic strategies for the future.
No takes yet. Share an insight, caveat, or question.
Riley et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: